Sam Huang
@Checkpoint Capital L.p.
Latest period2024 - Q3ReportedManaged Assets$201.574MTotal holdings16
Assets growth rate21.52%Assets growth rate (2-Q avg)16.19%Continuous growth in asset value2 quarters
Portfolio positions
This chart displays the top 10 holdings in Checkpoint Capital L.p.'s 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 16 positions.
Assets under management
The assets under management (AUM) of Checkpoint Capital L.p. over the past 10 years (40 quarters) show continuous growth in total asset value over the last 2 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 201.574M in assets, with a quarterly growth rate of 21.52% and a 2-quarter average growth rate of 16.19%. The portfolio is managed by Sam Huang, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
RYTMRhythm Pharmaceuticals Inc
| 17.25% | $34.755M 663,381 shares@ $52.4 avg price | Decreased -28.05% |
AXSMAxsome Therapeutics Inc
| 9.35% | $18.84M 209,632 shares@ $89.88 avg price | Decreased -27.9% |
AVDLAvadel Pharmaceuticals Plc
| 7.16% | $14.427M 1.1M shares@ $13.12 avg price | Decreased -3.35% |
PTGXProtagonist Therapeutics Inc
| 5.36% | $10.8M 240,000 shares@ $45.0 avg price | Decreased -32.39% |
ATYRAtyr Pharma Inc
| 1.52% | $3.056M 1.736M shares@ $1.77 avg price | Decreased -10.78% |
TRVITrevi Therapeutics Inc
| 0.42% | $835,000 250,000 shares@ $3.34 avg price | Decreased -50% |